Login / Signup

Anti-CD20 treatment for B-cell malignancies: current status and future directions.

Christiane NeumannCandice JamoisTina Nielsen
Published in: Expert opinion on biological therapy (2020)
Of the novel anti-CD20 antibodies, only obinutuzumab has shown consistently improved efficacy over rituximab in randomized pivotal trials in indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia. The Phase 3 GALLIUM trial demonstrated significant improvements in progression-free survival with obinutuzumab-based immunochemotherapy over rituximab-based immunochemotherapy. Novel combinations of obinutuzumab, including with chemotherapy-free options are being explored, such as with the newly approved combinations of obinutuzumab with venetoclax, ibrutinib, or acalabrutinib. The biggest unmet need remains in the treatment of diffuse large B-cell lymphoma; emerging options in this field include the use of CAR-T cells and T-cell bispecific antibodies.
Keyphrases
  • chronic lymphocytic leukemia
  • diffuse large b cell lymphoma
  • epstein barr virus
  • free survival
  • phase iii
  • clinical trial
  • phase ii
  • study protocol
  • hodgkin lymphoma
  • combination therapy